University of Kentucky

UKnowledge
Theses and Dissertations--Clinical and
Translational Science

Behavioral Science

2021

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor
Organoids to Predict Carboplatin Resistance
Justin W. Gorski
University of Kentucky, justin.gorski@gmail.com
Author ORCID Identifier:

https://orcid.org/0000-0002-4272-0183

Digital Object Identifier: https://doi.org/10.13023/etd.2021.392

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Gorski, Justin W., "Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict
Carboplatin Resistance" (2021). Theses and Dissertations--Clinical and Translational Science. 15.
https://uknowledge.uky.edu/cts_etds/15

This Doctoral Dissertation is brought to you for free and open access by the Behavioral Science at UKnowledge. It
has been accepted for inclusion in Theses and Dissertations--Clinical and Translational Science by an authorized
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained needed written permission statement(s)
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing
electronic distribution (if such use is not permitted by the fair use doctrine) which will be
submitted to UKnowledge as Additional File.
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and
royalty-free license to archive and make accessible my work in whole or in part in all forms of
media, now or hereafter known. I agree that the document mentioned above may be made
available immediately for worldwide access unless an embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s thesis including all
changes required by the advisory committee. The undersigned agree to abide by the statements
above.
Justin W. Gorski, Student
Dr. Jill M. Kolesar, Major Professor
Dr. Claire Clark, Director of Graduate Studies

UTILIZING PATIENT-DERIVED EPITHELIAL OVARIAN CANCER TUMOR
ORGANOIDS TO PREDICT CARBOPLATIN RESISTANCE

________________________________________
DISSERTATION
________________________________________
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Medicine
at the University of Kentucky
By
Justin Wayne Gorski
Lexington, Kentucky
Director: Dr. Jill M. Kolesar, Professor of Pharmacy
Lexington, Kentucky
2021

Copyright © Justin Wayne Gorski 2021
https://orcid.org/0000-0002-4272-0183

ABSTRACT OF DISSERTATION

UTILIZING PATIENT-DERIVED EPITHELIAL OVARIAN CANCER TUMOR
ORGANOIDS TO PREDICT CARBOPLATIN RESISTANCE
The development of patient-derived tumor organoids (TOs) from epithelial ovarian
cancer tumor obtained at the time of primary or interval debulking surgery has the potential
to play an important role in precision medicine.
Here, we utilize TOs to test front-line chemotherapy sensitivity and to investigate
genomic drivers of carboplatin resistance. We developed six high grade serous epithelial
ovarian cancer tumor organoids from tissue obtained during debulking surgery (2
neoadjuvant carboplatin exposed, 4 chemo-naïve). Each organoid line was screened for
sensitivity to carboplatin at four different doses (100, 10, 1 and 0.1µM). Cell viability
curves and resultant EC50 values were determined after normalizing to untreated negative
controls.
One organoid line, UK1254, was predicted to be resistant to carboplatin based on
EC50 value (50.2 µM) above clinically achievable Cmax. UK1254 had a significantly
shorter progression free survival (PFS) than the rest of the subjects (P=0.0253) and was
treated as a platinum-resistant recurrence. Subsequent gene expression analysis revealed
extensively interconnected differentially expressed pathways related to NF-kB, cellular
differentiation (PRDM6 activation) and linkage of B-cell receptor signaling to the PI3KAkt signaling pathway (PI3KAP1 activation).
This study demonstrates that patient derived tumor organoids can be developed
from patients at the time of primary or interval debulking surgery and possibly can be used
to predict clinical platinum sensitivity status or to investigate drivers of carboplatin
resistance.
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CHAPTER 1. INTRODUCTION
1.1

Background
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic

malignancy in the United States. In 2021, it is estimated that 21,410 women will be
diagnosed with ovarian cancer and that it will be responsible for 13,770 deaths in the U.S.
[1]. The high mortality rate is primarily due to the predominance of late stage detection
and the high rate of recurrence due to chemotherapy resistance.
The current standard of care treatment for advanced stage disease includes surgical
debulking, with a goal of removing all macroscopic disease (R0 cytoreduction), in
combination with platinum-based neoadjuvant or adjuvant chemotherapy [2]. Despite this
aggressive front-line treatment more than 80% of patients will recur [3]. Historically, the
platinum free interval (PFI; time from the last dose of front-line adjuvant platinum-based
chemotherapy to the detection of recurrence) is used to classify patients into platinum
sensitive, resistant and refractory groups [4]. These groups have considerably different
clinical outcomes. “Platinum sensitive” individuals (PFI ≥6 months) comprise
approximately 75% of recurrences and have a median overall survival (OS) of 24-36
months. Conversely, 15% of patients are “platinum resistant” (PFI <6months) with a
median OS of only 9-12 months. Disease in “platinum refractory” individuals progresses
during treatment and makes up about 10% of recurrences. This group suffers the worst
outcome with a median OS of 3-5 months [5-6]. For the clinician, the choice of treatment
in the platinum resistant or refractory setting is difficult. Response rates to non-platinum
based cytotoxic chemotherapy are similar and overall quite poor: topotecan (20%),
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gemcitabine (19%), liposomal doxorubicin (26%), oral etoposide (27%), docetaxel (22%),
weekly paclitaxel (21%) [2].

1.2

Role of Chemosensitivity Assays
Despite the dramatic difference in outcomes between platinum sensitive, resistant

and refractory groups there is not a validated method to predict clinical response to
platinum-based chemotherapy and all individuals receive the same up-front therapy.
Chemosensitivity assays using patient derived tumor cells have been increasingly explored
to satisfy this unmet clinical need. In fact, some National Comprehensive Cancer Network
(NCCN) centers employ the use of chemosensitivity assays to guide management in the
face of recurrence when there are multiple equivalent chemotherapy options available [2].
Early investigations primarily using extreme drug resistance assays [7-8] or phenotypic
drug response assays [9] which were initially promising but have failed to produce
sufficient evidence of efficacy to change the standard of care or warrant reimbursement
[10]. However, patient derived tumor organoid (TO) chemosensitivity assays have recently
emerged as a more accurate model of in vivo tumor biology [11] and have shown promise
to predict clinical chemotherapy response in vitro [12].

1.3

Primary and Secondary Objectives
Here, we developed and validated six patient derived epithelial ovarian cancer TO

lines which were subsequently screened for sensitivity to front line standard of care
chemotherapeutic agents. TO genetic sequencing was used to identify genomic
determinants of carboplatin resistance. Our primary objective was to assess the ability of
2

TOs to predict clinical outcomes to initial chemotherapy. Secondary objectives included
identification of an integrated genomic signature of platinum resistance in EOC.
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CHAPTER 2. MATERIALS AND METHODS
2.1

Research Subjects
Women with suspected or histologically confirmed epithelial ovarian with a plan to

undergo cytoreductive surgery were eligible for study inclusion. All patients who were
potentially eligible were approached for enrollment by trained clinical research staff during
their pre-operative clinic visit which occurred one to four weeks before the scheduled
debulking surgery. Written informed consent was obtained from all subjects and they were
enrolled in the Total Cancer Care Protocol: A Lifetime Partnership with Patients Who
Have or May be at Risk of Cancer (MCC 17-MTB-01, UK IRB #44224). Clinical outcome
data was collected prospectively, deidentified and correlated with TO chemosensitivity
assay and genomic data by an honest broker. Disease assessment were performed per
routine clinical practice by the treating provider to assess progression free survival (PFS).
Patient outcomes were followed until all patients demonstrated clinical evidence of
recurrence or progression as defined by RECIST version 1.1 criteria [13]. The study was
conducted according to the guidelines of the Declaration of Helsinki, and approved by the
Institutional Review Board of the University of Kentucky.

2.2

Tumor Organoid (TO) Development and Validation
Fresh ovarian tumor tissue was obtained from patients at the time of debulking

surgery, dissociated into a single ovarian cancer cell suspension, and established in
Matrigel® Growth Factor Reduced Basement Membrane Matrix (Corning) in vitro using
factor defined media [14-15]. TOs were passaged at least two times to eliminate stromal
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cells by digesting the Matrigel® matrix with trypsin-EDTA/TrypLE followed by gentle
mechanical dissociation. Once ovarian cancer TOs were established, the TOs were fixed,
representative sections were H&E stained and compared with primary tumor by a board
certified pathologist.

2.3

Chemosensitivity Screens
Established TOs were enzymatically dissociated into single cells, and plated in 384

well plates. The cells were cultured for 72 hours prior to administration of carboplatin at
five different doses (0, 100, 10, 1 and 0.1µM). After culturing for an additional 72 hours,
organoids were incubated with Hoescht nuclear counterstain and imaged on a spinning
disc confocal high content imager. After imaging was completed, viability was measured
by employing the MTS assay (Promega). Raw data were generated in triplicate, and the
average cell viability for each drug concentration was determined after normalizing values
to untreated negative controls. Cell viability curves were generated, and EC50 values were
determined.

2.4

Sequencing Methods
The Tempus xT next generation targeted oncology sequencing assay was utilized to

perform a gene mutation and expression analysis for all six generated TO cell lines. TO
total nucleic acid was extracted and digested by proteinase K. RNA was purified from the
total nucleic acid by DNase-I digestion. DNA and RNA sequencing was performed as
previously described [16]. Briefly, 100ng of DNA for each TO sample was mechanically
sheared to an average size of 200 base pairs (bp) using a Covaris ultrasonicator. DNA
5

libraries were prepared using the KAPA Hyper Prep Kit, hybridized to the xT probe set,
and amplified with the KAPA HiFi HotStart ReadyMix. 100ng of RNA for each tumor
sample was heat fragmented in the presence of magnesium to an average size of 200 bp.
Library preps were hybridized with the IDT xGEN Exome Research Panel and target
recovery was performed using Streptavidin-coated beads, followed by amplification with
the KAPA HiFi Library Amplification Kit. The amplified target-captured DNA tumor
libraries were sequenced to an average unique on target depth of 500x on an Illumina
HiSeq 4000. Samples were further assessed for uniformity with each sample required to
have 95% of all targeted bp sequenced to a minimum depth of 300x [17].

2.5

Gene Mutation and Gene Expression Bioinformatic Analysis
For somatic mutation analysis, an oncoplot was generated based on the maftools [18]

package to visualize non-silent somatic mutations in DNA repair genes. For gene
expression analysis, genes that were unexpressed or lowly expressed in all samples (no
sample with counts per million mapped reads (CPM) > 1) were excluded from analysis.
The differential expression analysis of the carboplatin-resistant versus carboplatinsensitive groups was performed using the edgeR package [19]. Significantly differentially
expressed genes were identified based on a threshold of false discovery rate (FDR) < 5%
and annotated for gene ontology terms. A volcano plot was generated for results
visualization. All these analyses were performed using R 4.0.3. The pathway enrichment
and network analysis were performed using Qiagen’s Ingenuity Pathway Analysis (IPA)
system for the core analysis of the RNA sequencing data and overlaid with the Global
Molecular Network Overlay in the IPA knowledge base.
6

2.6

Statistical Analysis
The classification of each TO cell line as carboplatin-sensitive or carboplatin-

resistant was based on the comparison of the carboplatin EC50 value to the clinically
achievable plasma concentration of carboplatin. Resistant cell lines were defined as having
a carboplatin EC50 above the plasma Cmax of carboplatin [20]. Sensitive TO cell lines had
a carboplatin EC50 within achievable plasma concentrations. One sample t-test was used
to compare carboplatin-resistant and pooled carboplatin-sensitive EC50 values using
GraphPad Prism 8. The Kaplan–Meier method was used to estimate PFS curves for
platinum-sensitive and carboplatin-resistant patients. The PFS curves were compared via
the log-rank test using R 4.0.3. A p < 0.05 was considered as statistically significant.
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CHAPTER 3. RESULTS
3.1

Subject Demographic and Treatment Characteristics
The tumor samples used to generate the TO lines were derived from a relatively

homogenous population. All subjects had histologically proven advanced-stage epithelial
ovarian or fallopian tube cancer. Histologic subtype was exclusively high-grade serous.
Primary disease sites were localized to the ovary (75%) and fallopian tubes (25%). One
TO line (UK1393) was generated from a metastatic implant in the omentum, but all others
were developed from the primary site of disease (Table 1).

Table 1. Demographic characteristics of included subjects.

1

ID

Age

TNM Stage

UK1236

48

ypT3cN0M1

UK1254

49

UK1267

FIGO

Primary Site

Histology

Grade

IIIC

Ovary

Serous

3

ypT3cNX

IIIC

Ovary

Serous

3

55

T2bN0

IIB

Fallopian Tube

Serous

3

UK1393

46

T3cNX

IIIC

Ovary1

Serous

3

UK2238

58

T3aN1b

IIIA

Fallopian Tube

Serous

3

UK2326

62

T3cNX

IIIC

Ovary

Serous

3

Stage

TO developed from metastatic omentum implant.
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Treatments courses of the study subjects were also relatively homogenous. All
participants were treated with a platinum and taxane doublet. One subject’s taxane therapy
(UK1236) was switched from paclitaxel to abraxane due to allergic reaction. Most subjects
were chemonaïve (66.7%) at the time of debulking surgery. However, two subjects
(33.3%) were exposed to three cycles of neoadjuvant chemotherapy before interval
debulking surgery. Optimal cytoreduction was achieved in 50% of patients and all other
debulking surgeries achieved <0.5cm of residual disease. Most patients did not receive
maintenance therapy. However, one patient received olaparib and another was enrolled in
a Gynecologic Oncology Group (GOG) clinic trial studying the effects of the PARP
inhibitor rucaparib and immunotherapy agent nivolumab [21]. It is uncertain if the patient
received study drugs or placebo (Table 2).

9

Table 2. Treatment courses of enrolled subjects.

ID
UK1236

Residual
Disease (cm)
0

UK1254

<0.5

UK1267

0

Neoadjuvant
carboplatin &
paclitaxel1 x1
cycle; carboplatin
& abraxane x 2
cycles
carboplatin &
paclitaxel x 3
cycles

Maintenance

carboplatin &
abraxane x3 cycles

None

carboplatin &
paclitaxel x 3 cycles

GOG 3020:
rucaparib v.
placebo &
nivolumab v.
placebo
None

carboplatin &
paclitaxel x 6 cycles
UK1393
0
None
carboplatin &
None
paclitaxel x 6 cycles;
bevacizumab cycles 26
UK2238
<0.5
None
carboplatin &
olaparib
paclitaxel x 6 cycles
UK2326
<0.5
None
carboplatin &
None
paclitaxel x 6 cycles
1
Carboplatin (AUC = 6) and paclitaxel (175 mg/m2 ) IV every 21 days was used as the
standard dosing regimen.

3.2

None

Adjuvant

Tumor Organoid Validation
Histologic concordance between each ovarian cancer TO cell line and its respective

primary ovarian cancer tumor sample was confirmed. After the establishment of the TO
cell line, a sample of it was formalin-fixed and stained using hematoxylin and eosin (H&E)
(Figure 1).
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UK1236

UK1254

UK1267

UK1393

UK2238

UK2326

Figure 1. Hematoxylin and eosin (H&E) micrographs of established epithelial ovarian
cancer tumor organoids.

Primary tumor samples for each established cell line were also formalin-fixed and
H&E stained. The TO sample and respective tumor sample were compared. All TO lines
were determined to be similar to their respective parental tumor samples after examination
by a board-certified pathologist.
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3.3

Chemosensitivity Screens
Cell viability curves and resultant EC50 values were determined for all generated TO

lines (Table 3).

Table 3. Cell viability EC50 values for each TO cell line when treated with carboplatin and
subject progression free survival (PFS).

1

ID

Carboplatin EC50 (µM)

UK2326
UK1267
UK2238
UK1236
UK1393
UK1254

0.8
1.1
3.3
28.5
44.8
50.21

PFS
(days)
398
338
391
579
445
252

Above clinically achievable plasma Cmax.
The mean EC50 value for UK1254 exceeded achievable plasma carboplatin Cmax

(50 µM) and was the highest of all TO line EC50 values. Conversely, all other TO lines
were determined to be sensitive to carboplatin, with a significantly lower pooled cell
viability EC50 mean value (p = 0.018). All carboplatin-sensitive TO cell lines demonstrated
EC50 values within the range of achievable plasma concentrations (Figure 2).
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p = 0.018

Figure 2. Scatter plot demonstrating cell viability EC50 mean ± SEM for the carboplatin
resistant (UK1254) and pooled carboplatin sensitive TO lines when treated with
carboplatin. One sample t-test was used to compare resistant and sensitive EC50 values
(p=0.018).

3.4

Clinical Outcomes
The number of days from completion of adjuvant chemotherapy until recurrence or

progression as demonstrated by RECIST criteria was used to determine each subject’s
progression free survival (PFS) (Table 3). UK1254 had a significantly shorter PFS than
the rest of the subjects with a p = 0.025 (Figure 3).
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Figure 3. (A). Kaplan Meier Survival plot demonstrating progression free survival (PFS)
of enrolled subjects when stratified by carboplatin TO chemosensitivity assay results.
Platinum Resistant (red): UK1254. Platinum Sensitive (blue): UK1236, UK1267,
UK1393, UK2238 and UK2326. (B.) Plot demonstrating number of subjects at risk for
progression in platinum resistant and sensitive groups.

Thus, clinical outcomes directly correlate with TO cell viability chemosensitivity assay
results.

14

3.5

Tumor Organoid Mutation Analysis
A limited mutation analysis was performed for all generated TO lines using the

Tempus xT gene panel. Genes that were mutated in multiple cell lines and a selection of
DNA repair genes were specifically interrogated to explore similarities in mutation profiles
between TO cell lines for all enrolled subjects (Figure 4).
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Figure 4. Oncoplot demonstrating the top mutated genes for all TO cell lines and select
DNA repair genes. Carboplatin Resistant: UK1254. Carboplatin Sensitive: UK1267,
UK2238, UK2326, UK1236 and UK1393.

As expected in high grade serous ovarian cancer (HGSOC), the most commonly
mutated gene was TP53 (4/6, 67%). The second most commonly altered genes were
FANCC (2/6, 33%) which is a critical component of the Fanconi Anemia core complex
[22], and NOTCH2 (2/6, 33%) which is a key part of the Notch signaling pathway that
controls normal morphological development of multicellular organisms. Genomic
mutations in the DNA repair genes were mostly relegated to intron alterations but also
notably include a BRCA1 frame shift deletion mutation in UK2238, BRIP1 missense
mutation in UK1254 and an ATM missense mutation in UK1267.

3.6

Tumor Organoid Gene Expression Analysis

We then performed a gene expression analysis using the RNA sequencing data in
Qiagen’s Ingenuity Pathway Analysis (IPA) to evaluate differences in expression and
pathways to better understand the mechanism of carboplatin resistance. All subjects had
TO RNA sequencing data available. A total of 71 genes were significantly differentially
expressed (FDR values < 0.05) between the carboplatin resistant TO and the carboplatin
sensitive TOs after appropriate thresholds were applied. Genes that met significance cutoff
criteria are represented in blue. Genes eliminated after thresholds were applied are
represented in red (Figure 5).
16

Figure 5. Volcano plot of the 71 differentially expressed genes identified when the
carboplatin resistant TO line (UK1254) is compared to the carboplatin-sensitive TO lines
(UK1236, UK1267, UK1393, UK2238, and UK2326).

The top upregulated and downregulated differentially expressed genes comparing
the carboplatin-resistant group to the carboplatin-sensitive group are displayed in Table 4.
In the top ten upregulated genes, many are involved in transmembrane transport, cellular
differentiation, and immune response modulation. In the top ten downregulated genes,
many are involved in regulation of cellular growth, cellular stress response, and lipid
metabolism. Notably, TMEM178B is not yet linked with an established biological
pathway identifier and may represent a novel finding. Note, a complete list of differentially
expressed genes is available in the appendix.
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Table 4. Top differentially expressed genes comparing the carboplatin-resistant group to
the carboplatin-sensitive group. (A) Upregulated pathways in carboplatin-resistant TO
compared to the carboplatin-sensitive TO group. (B) Downregulated pathways in
carboplatin-resistant TO compared to the carboplatin-sensitive TO group.
A. Upregulated
P Value
QValue
(FDR)
1.46E-15
2.26E-11

Gene

LogFC

Pathway ID

Pathway Description

1. AQP1

8.722968

GO:0022857

Transmembrane
transport activity
--Cell dedifferentiation

2. TMEM178B
3. RELN

6.489275
7.083244

1.30E-14
1.29E-13

1.01E-10
6.68E-10

--GO:0030154

4. ZNF723

8.998623

1.08E-12

4.20E-09

GO:0003700

5. HAVCR1

9.870356

3.29E-11

1.02E-07

GO:00023676

6. FXYD2

8.374937

8.24E-10

2.13E-06

GO:0030234

7. TGM3

6.3814

1.01E-09

2.24E-06

GO:0006464

8. OGFRL1

3.648762

1.25E-09

2.41E-06

GO:0007165

9. LIPC

5.511889

2.91E-08

4.31E-05

GO:0006629

10. ADGRF2

9.051376

3.06E-08

4.31E-05

GO:0007165

Lipid metabolic
process
Signal transduction

DNA Binding
transcription factor
activity
Immune system
process
Enzyme regulator
activity
Cellular protein
modification process
Signal transduction

Pathway ID

Pathway Description

1. MAPK1

B. Downregulated
LogFC
P Value
QValue
(FDR)
-10.0724
2.43E-09
4.19E-06

GO:0030154

Cell differentiation

2. ARNT2
3. STRA6

-9.9226
-5.39401

3.89E-07
6.80E-06

0.000463
0.00405

GO:0006950
GO:0006629

4. RBP1

-5.05496

8.05E-06

0.004168

GO:0006629

5. ANTXR1

-5.06802

1.13E-05

0.005453

GO:0007010

6. LTBP1

-4.19728

3.59E-05

0.01285

GO:0006464

7. AXIN2

-5.6952

4.47E-05

0.01442

GO:0008283

8. SLFN11

-3.93117

8.66E-05

0.02396

GO:0006950

Response to stress
Lipid metabolic
process
Lipid metabolic
process
Cytoskeleton
organization
Cellular protein
modification process
Cell population
proliferation
Cell response to stress

Gene

18

9. PHACTR1

-5.39943

9.58E-05

0.025592

GO:0007010

10. LYPD1

-4.77696

0.000116

0.030426

GO:0007267

Cytoskeleton
organization
Cell-cell signaling

Next, an in-depth network analysis used the RNA sequencing data to determine
cell-specific pathways impacted by carboplatin resistance. Notably, leukocyte
extravasation signaling, GP6 signaling, cardiac hypertrophy signaling, and PI3K signaling
in B lymphocytes were predicted to be increasingly activated in the carboplatin-resistant
TO, as demonstrated by pathways represented with shades of orange. Conversely, the
CD40 signaling, HER-2 signaling, and MSP-RON signaling in macrophages were
suspected to have decreased activation in the carboplatin-resistant phenotype and are
represented in shades of blue (Figure 6A). Pathways that were differentially activated and
downregulated were found to be extensively interconnected (Figure 6B).

19

Figure 6. Differential expression analysis of carboplatin-resistant TO versus carboplatinsensitive subjects. (A) Pathway analysis of genes differentially expressed between
carboplatin-resistant and carboplatin-sensitive TOs. (B) Network analysis of the pathways
differentially expressed between carboplatin-resistant and carboplatin-sensitive TOs.

To better assess the clinical applicability of the gene expression analysis, we
converted the pathway analysis to a heatmap with analysis by disease and organ system
(Figure 7A). The length of the box denotes the -log(p-value). The color of the boxes
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correlates with the z-score, with the intensity of blue representing z ≤ 0 and the intensity
of orange representing z ≥ 0. Pathways related to organismal injury and abnormalities,
cancer, gastrointestinal disease, and reproductive system disease predominated. This

suggests that carboplatin resistance is partly mediated by the alteration of injury-associated
biological mechanisms and well-established cancer-related pathways.
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Figure 7. Gene network analysis between carboplatin-resistant and carboplatin-sensitive
subjects. (A) Heatmap of the network analysis of genes differentially expressed between
carboplatin-resistant and carboplatin-sensitive TOs by organ and disease system. The color
and intensity of the boxes correlate with the z-score. Blue represents z ≤ 0, and orange
represents z ≥ 0. (B) Heatmap of network analysis separated by cancer disease process. (C)
Disease system pathways involved in carboplatin resistance are shown through network
analysis of genes differentially expressed between carboplatin-resistant and carboplatinsensitive TOs.

Finally, we performed network mapping using IPA with Global Network Overlay
to explore the effect of carboplatin resistance on genes that were determined to be
significantly altered between the carboplatin resistant TO and the carboplatin sensitive
group. Upregulated expression is denoted in red with the color intensity corresponding to
increased significance. Conversely, downregulated expression is notated in green with
color intensity again corresponding to increased significance. Network mapping results
were filtered by statistically significant p-values with expression fold changes ≥ 0. We
focused on the most significantly altered gene network (Figure 8A) and the second most

significantly altered gene network (Figure 8B). Exploration of the most significantly
altered network map (Figure 8A) revealed an interplay between various pathways all
centered around NF-kB when the carboplatin resistant TO was compared to the carboplatin
sensitive TOs. The second most significantly altered network (Figure 8B) demonstrates
interplay between pathways involved in cellular differentiation (PRDM6 activation) and
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linkage of B-cell receptor signaling to the PI3K-Akt signaling pathway (PI3KAP1
activation) [23].

(A)
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(B)
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Figure 8. Network analysis of genes differentially expressed between carboplatin resistant
and carboplatin sensitive TOs. Network mapping by Qiagen IPA with Global Network
Overlay demonstrates the most significant gene network (A) and second most significant
gene network (B).
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CHAPTER 4. DISCUSSION
4.1

Overview

This prospective, observational, exploratory study demonstrates that tumor
organoid (TO) development from chemo-naïve and neoadjuvant chemotherapy exposed
epithelial ovarian cancer patients is both feasible and potentially predictive of clinical
response to front line therapy. Commiserate with this study, other groups have successfully
developed TOs from epithelial ovarian cancer patients and utilized TOs to screen for
sensitivity to chemotherapeutic agents [24]. However, to our knowledge, this study is the
first to report prospective correlation of carboplatin chemo-sensitivity screening with
progression free survival (PFS).

4.2

Mutation Analysis Interpretation

Our mutation analysis provides insight into the genetic underpinnings driving
tumorigenesis in our population. As expected in high grade serous ovarian cancer,
alterations in the tumor suppressor gene TP53 was the most common mutation. The second
most commonly altered gene, FANCC, is a critical component of the Fanconi Anemia core
complex. A dysregulated Fanconi Anemia pathway is frequently identified in epithelial
ovarian cancer due to its extensive interconnection with DNA repair pathways [25].
Missense mutations in Notch2 occurred in two of the carboplatin sensitive TO lines
(UK1267 and UK1393). A wide range of cancer types have been found to overexpress
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Notch2 or to exhibit Notch2 gain-of-function mutations. Overactive Notch2 signaling has
been linked to the dysregulation of certain miRNAs, to tumor-associated stromal cell input,
and to modulation of internal and external stimulation conditions in tumor cells which
contribute to chemo and radio-resistance [26]. If the Notch2 missense mutations identified
in these ovarian cancer TO cell lines renders the Notch 2 protein nonfunctional then a
dysregulated Notch 2 signaling pathway may be partially responsible for the observed
carboplatin sensitivity. Exploration of the mutation patterns of a selection of DNA repair
genes reveals mostly intron mutations in the carboplatin sensitive cohort which likely do
not impact function. However, notably in the carboplatin resistant TO cell line UK1254, a
BRIP1 missense mutation was identified but the functional significance of this mutation
is uncertain [27].

4.3

Gene Expression Analysis Interpretation

Although the gene panel mutation analysis provides some insight into the molecular
drivers of tumor cell growth, they do not paint a complete picture of carboplatin resistance
in UK1254. Our comparative gene expression analysis using TO RNA sequencing and
IPA pathway analysis provides insight into the biological processes that are potentially
driving chemotherapy resistance. Exploration of the most significantly altered network
map (Figure 8A) revealed an interplay between various pathways all centered around NFkB when the carboplatin resistant TO was compared to the carboplatin sensitive TOs. In
addition to apoptosis threshold determination, the transcription factor NF-kB regulates
multiple aspects of the innate and adaptive immune functions and serves as a pivotal
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mediator of inflammatory responses [28]. It has been well established that various
dysregulated signaling pathways can activate the NF-κB signaling pathway in ovarian
cancer which in turn promotes chemoresistance, cancer stem cell maintenance, metastasis
and immune evasion [29-31]. The second most significantly altered network (Figure 8B)
demonstrates interplay between pathways involved in cellular differentiation (PRDM6
activation) and linkage of B-cell receptor signaling to the PI3K-Akt signaling pathway
(PI3KAP1 activation) [23]. These functions combined may be responsible for the observed
clinical and in vitro carboplatin resistance of UK1254. Discovery of these cellular
alterations provides novel insight into the mechanism of carboplatin resistance in UK1254
and may be able to be exploited with targeted therapy.
We found that in the top ten upregulated genes, many have been linked to platinumbased chemotherapy resistance (AQP1 [32-33] and RELN [34]), to poor prognosis when
exposed to platinum agents (LIPC [35] and FXYD2 [36]) or increased invasiveness
(ADGRF2 [37]) when overexpressed. Notably, upregulation of TMEM178B and ZNF723
have not been directly linked to carboplatin resistance and understanding of their
biological function in cancer remains limited. Interestingly, transmembrane protein 178B,
the gene product of TMEM178B, has been identified as a novel downstream target of the
nuclear factor kappa beta (NF-κB) ligand/phospholipase C gamma-2 signaling axis that
modulates osteoclast activation [38]. NF-𝜅𝜅B is a pleiotropic transcription factor key which
determines the death threshold of cancer cells after exposure to platinum drugs and
inhibition of NF-𝜅𝜅B sensitizes cells to the effects of platinum-based chemotherapy [39].
Thus, overexpression of TMEM178B may produce a biological effect similar to
upregulation of NF-𝜅𝜅B and warrants further investigation. In the top ten downregulated
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genes, many have been linked to platinum-based chemotherapy resistance (MAPK1[4041], SLFN11 [42] and LYPD1 [43]), poor clinical outcome (ARNT2 [44]) or oncogenesis
via constitutive activation of wnt/𝛽𝛽 signaling (AXIN2 [45]) when under expressed.

4.4

Strengths and Limitations

The main strength of our study is that we were able to successfully correlate TO
chemosensitivity assay results with clinical progression free survival (PFS) despite only
including six subjects in this analysis and that we have identified genomic predictors of
response. This is in contrast to prior ovarian organoids publications which report in vitro
sensitivity to antineoplastics, but fail to include correlation with clinical outcome and
genomic predictors of resistance. Genomic predictors of platinum resistance performed at
initial surgery have the potential to guide subsequent clinical management with the
advantages of convenience and speed over organoid sensitivity testing [24, 46-48]. The
major limitation of our study is the small sample size. We intentionally only utilized
advanced stage, high grade serous epithelial ovarian cancer specimens in an effort to create
the most clinically and genetically homogenous sample possible. Although this strategy
decreased the number of subjects eligible for inclusion in this study, it reinforces the
clinical applicability of our results to this specific patient population with an unmet clinical
need. In addition, focusing on this homogenous population, limits the generalizability of
our findings to other types of ovarian cancer. An additional limitation of this study is the
lack of normal tissue organoid controls. At the time of debulking surgery, some subjects
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lacked normal human ovarian tissue due to complete destruction by malignancy. Thus,
matched normal ovarian tissue was unavailable for culture.

4.5

Clinical Impact

Early stratification of patients into carboplatin sensitive and resistant cohorts,
before clinical recurrence, may help delineate who should receive maintenance therapy
with bevacizumab or a biosimilar. Furthermore, the combined use of TO chemosensitivity
assay results and genomic markers of carboplatin resistance into a predictive scoring
system of recurrence may provide the basis for additional cycles of cytotoxic
chemotherapy beyond the traditional six. We envision that if the methodologies utilized
here are applied to a larger cohort we could develop a novel epithelial ovarian cancer
predictive scoring system. Similar systems such as the Oncotype DX test is currently
standard of care for adjuvant chemotherapy stratification in early stage, ER+, HER2/neu
negative breast cancer and intermediate risk prostate cancer. The development of an
accurate scoring system that predicts an individual’s front line PFS has the potential to
change the standard of care for high grade serous ovarian cancer treatment and improve
outcomes for thousands of patients every year.

4.6

Conclusions
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Tumor organoid (TO) development from chemo-naïve and neoadjuvant
chemotherapy exposed epithelial ovarian cancer patients is both feasible and potentially
predictive of clinical response to front line therapy. An integrated TO mutation and gene
expression analysis can be utilized to investigate molecular mechanisms of carboplatin
resistance. Combination of these methods may provide the basis for development of a
predictive recurrence scoring system that can be utilized to tailor maintenance and
additional adjuvant therapy to individual patient needs.
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CHAPTER 5. FUTURE DIRECTION
5.1

Overview

The next steps of our study will focus on validation of the carboplatin resistance
signature identified in the platinum resistant tumor organoid line UK1254. We
acknowledge that our study is limited by sample size and that many attempts have failed
to understand the mechanism of carboplatin resistance in high grade serous epithelial
ovarian cancer. Despite decades of research, no reliable clinical predictors of platinum
resistance have been identified and all patients continue to receive platinum based
chemotherapy in the front-line setting.
We propose that we must validate the recently discovered set of genomic drivers of
platinum resistance with a large cache of ovarian cancer somatic whole exome sequencing
(WES) and RNA sequencing (RNASeq) data and with a tissue microarray (TMA). Our
study will mostly focus on utilization of subjects with similar histology and grade to the
developed TO cell lines i.e. “Type II” epithelial ovarian cancer [49]. Unique to our study,
both of these validation resources will be stratified based on subject sensitivity to
carboplatin. This will allow for a homogenous and properly stratified cohort.

5.2

Specific Aims
Over the last few years we have developed a bank of tumor organoids (TO) from

Total Cancer Care (TCC) consented ovarian cancer patients at the University of Kentucky
Markey Cancer Center (UKMCC). Established TOs were assessed for sensitivity to
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carboplatin in vitro which correlate to the clinical outcome measure, progression free
survival (PFS). Our TO models have comprehensive clinical, demographic and genomic
profiles and will serve as the “discovery set” for identifying a high grade serous ovarian
cancer carboplatin resistance signature. We propose to validate our platinum resistance
signature with a larger TCC/ORIEN cohort complied from eight other member institutions
and with a tissue microarray (TMA) that will be created with tumor tissue from our
UKMCC ovarian cancer TCC/ORIEN subjects.

Aim 1: Validate the identified platinum-resistance signature in a larger population with
the inter-member Total Cancer Care/Oncology Research Information Exchange Network
(TCC/ORIEN) ovarian cancer genomic database.

Hypothesis: The platinum resistance signature will be valid when tested against a large
population of clinically stratified ORIEN subjects.

Aim 2: Validate the genomic platinum-resistance signature with protein expression
patterns using an ovarian cancer tissue microarray.

Hypothesis: The platinum resistance signature can be reproduced with protein expression
patterns.

The proposed studies will investigate the underlying tumor biology of platinum
resistant ovarian cancer while controlling for various clinical factors that influence
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outcomes. Validation of a platinum-resistance signature in ovarian cancer is the first step
in identifying patients unlikely to respond to current front-line therapy.

Early

identification of inherent platinum resistance could help the treating clinician alter the
chemotherapeutic regimen since these patients derive little clinical benefit from current
treatment approaches.

5.3

Innovation

The next step of our study is innovative because the outcome (validated biomarker
profile of inherent platinum resistance) does not currently exist. Additionally, no other
population-based genomic study has been able to properly contextualize somatic
sequencing with as much accurate treatment information as the ORIEN database provides.
Capitalizing on these innovative features will allow for the identification and validation of
novel biomarkers that can be used to predict response to cytotoxic chemotherapy agents in
the frontline setting. This may lay the ground work to change the upfront treatment
paradigm in ovarian cancer.

5.4

Experimental Approach
We plan to utilize the results of the epithelial ovarian cancer tumor organoid

mutation and differentially expressed gene (DEGs) analysis as the discovery set [50]. The
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identified platinum resistance signature will be validated with the ORIEN Avatar database
and a tissue microarray (TMA).

Aim 1: We will evaluate the performance of our prediction models based on the
external ORIEN cohort. Included subjects will be divided into “Type I" and “Type II"
subtypes based on the reported histology and grade. Low grade serous and other types of
cancers that fit the “Type I” subtype are usually inherently platinum resistant. Often times,
carboplatin is not even offered to these patients since the efficacy us low [5]. Thus, we will
mostly focus on the “Type II” subtype since almost all of these patients are treated with
carboplatin.
Statistical measures such as sensitivity, specificity and the area under the receiver
operator characteristic (ROC) curve and area under the ROC curve (AUC) will be
calculated. It has been reported that a prediction model based on clinical factors yielded
an AUC of 0.63 [51]. We will assess whether our prediction model outperforms the model
reported in the literature (i.e. whether the AUC from our model is greater than 0.63). We
expect our model will achieve an AUC of 0.8.
Finally, we will compare gene mutation and expression profiles between “Type I”
and “Type II” subjects in order to identify similarities that may explain carboplatin
resistance in the “Type I” group. Specifically, the Fisher’s exact test will be used to
compare gene mutation frequency and the edgeR method [19] will be used to compare
gene expression level between the two subtypes. Multiple comparisons adjustment will
be

performed

based

on

the Benjamini-Hochberg procedure.

Differentially

mutated/expressed genes will be identified based on a false discovery rate threshold of
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0.05. In addition, gene set enrichment analysis (GSEA) will be performed to identify
enriched pathways.

Aim 2: All ovarian cancer subjects enrolled in TCC/ORIEN at the UKMCC will be
screened for available banked tumor tissue. Formalin fixed paraffin embedded (FFPE)
blocks will be screened for quality with hematoxylin & eosin (H&E) sections and reviewed
by a pathologist. Subjects will be divided in to “Type I” and “Type II” ovarian cancer
groups. The included specimens will be further stratified based on clinical sensitivity to
carboplatin and divided into two additional groups: carboplatin sensitive and carboplatin
resistant. Next, two cores of each block will be incorporated into a TMA block.
Immunohistochemical (IHC) staining of the TMA block for proteins of interest will be
performed by the University of Kentucky Biospecimen Procurement and Translational
Pathology Shared Resource Facility (UK BPTP SRF).

5.5

Preliminary Data and Progress
We have already taken the following steps toward completion of this study:
•

Applied for and been awarded a $25,000 grant from the Oncology Research
Information Exchange Network (ORIEN) led by co-principal investigators
Justin W. Gorski, MD and Frederick R. Ueland, MD.

•

Drafted and obtained approval for the study “Utilization of Integrated
Genetic Analysis to Predict Clinical and Therapeutic Outcomes in
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Gynecologic Oncology” from the University of Kentucky Intuitional
Review Board (IRB), Protocol #50767, Re-Approved 1/11/21.
•

Drafted and obtained approval for a statement of work (SOW) to lead an
ORIEN inter-member project to build a clinically stratified database of
ovarian cancer somatic WES and RNASeq data compiled from nine
institutions throughout the United States. We have successfully recruited
the following institutions to join our efforts:
1. Moffitt Cancer Center
2. University of Colorado
3. Rutgers Cancer Institute of New Jersey
4. University of Southern California Norris Comprehensive Cancer
Center
5. University of Utah Huntsman Cancer Center
6. University of Oklahoma Stephenson Cancer Center
7. Roswell Park Cancer Institute
8. Indiana University Simon Cancer Center

Aim 1: We have obtained genomic and clinical data for a total of 269 ORIEN
Avatar subjects (Table 5). We are able to explicitly classify 28 patients as “Type 1” and
167 patients as “Type 2”. Unfortunately, we have 74 patients who are not able to be
explicitly classified since the grade is listed as “unknown, not applicable or cannot be
assessed” in the clinical data from other ORIEN institutions.
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Table 5. Number of epithelial ovarian cancer ORIEN Avatar database subjects stratified
based on histology and grade.
Type of Ovarian Cancer

Number of Subjects

Type I

28

Type II

167

Unknown

74

Total

267

A sample of 167 “Type II” ORIEN Avatar patients in the validation cohort
(assuming 25% platinum resistant and 75% platinum sensitive [52]) will provide
98% power to detect a significantly higher AUC of our prediction model compared to the
model in the literature based on a one-sided z-test at 5% significance level.

Aim 2: We have recruited the University of Kentucky Biospecimen Procurement and
Translational Pathology Shared Resource Facility (UK BPTP SRF) to build the tissue
microarray. 99 total UKMCC subjects have been identified as having available tumor
tissue. FFPE blocks are currently being screened for quality and then will be divided into
“Type I”, “Type II”, “carboplatin sensitive” and “carboplatin resistant” cohorts as
previously described.

5.6

Study Limitations
Possible Interdependence of Aims: It may be viewed that Aim 2 is dependent on

Aim 1. However, no matter the outcome of Aim 1, creation of a large clinically-stratified
genomic database of ovarian cancer patients (Aim 1) and an ovarian cancer tissue
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microarray (Aim 2) are valuable resources that will provide insight into the mutational,
gene expression and proteomic landscape of platinum-resistant ovarian cancer.

5.7

Next Steps
Aim 1: Currently, the clinical data from ORIEN member institutions is being cleaned

and analyzed. This laborious process is necessary to be able to properly stratify subjects
into carboplatin sensitive and carboplatin resistant cohorts. Once the subjects are properly
stratified, we will be able to run the mutation and gene expression analysis as proposed
above.
Aim 2: The University of Kentucky Biospecimen Procurement and Translational
Pathology Shared Resource Facility (UK BPTP SRF) is currently screening a total of 99
tumor specimens from UKMCC ovarian cancer subjects and then they will stratify the
tumor samples and build the tissue microarray. Once, the mutation and gene expression
validation analysis is complete, we will compile a correlative list of candidate proteins and
begin validating antibodies for immunohistochemistry staining.
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APPENDIX
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APPENDIX 1. COMPLETE LIST OF DIFFERENTIALLY EXPRESSED GENES
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A. Complete List of Upregulated Differentially Expressed Genes
Gene Symbol
AQP1
TMEM178B
RELN
ZNF723
HAVCR1
FXYD2
TGM3
OGFRL1
LIPC
ADGRF2
SLC20A2
CCBE1
SIM2
HTR6
TP63
ARHGAP29
ZNF702P
MT1A
GLS
SIRPG
ABHD12B
CRLF1
ERVH48-1
DPP4
DSCAML1
SNX25
BTBD16
ARHGAP4
JAG1
GABRB3
ANKRD2
KCNQ3
SLC66A1L
UGT2B17
TNFSF18
KCNJ15

logFC
8.72296804
6.48927461
7.08324445
8.99862304
9.87035567
8.37493724
6.38140039
3.64876223
5.51188931
9.0513764
3.04718904
6.5099096
6.32271726
7.94986715
4.97541291
3.03290502
3.39126355
6.24789528
3.79936543
7.54913104
6.73069519
6.73263901
8.03551356
3.68879445
3.47224113
3.18652714
6.53206726
3.84509158
2.59779767
4.91616659
4.86381221
5.42149835
4.78522635
5.41070458
5.73794232
4.26008825
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PValue
1.46E-15
1.30E-14
1.29E-13
1.08E-12
3.29E-11
8.24E-10
1.01E-09
1.25E-09
2.91E-08
3.06E-08
3.58E-07
4.69E-07
1.18E-06
1.24E-06
1.40E-06
1.56E-06
1.80E-06
2.21E-06
3.06E-06
4.01E-06
4.50E-06
4.82E-06
5.38E-06
7.31E-06
8.06E-06
8.16E-06
8.34E-06
1.56E-05
1.82E-05
1.86E-05
1.87E-05
1.93E-05
2.16E-05
2.97E-05
3.10E-05
3.16E-05

FDR
2.26E-11
1.01E-10
6.68E-10
4.20E-09
1.02E-07
2.13E-06
2.24E-06
2.41E-06
4.31E-05
4.31E-05
0.00046273
0.00051891
0.00120412
0.00120412
0.00127749
0.00134327
0.00146738
0.00171313
0.00226043
0.00282587
0.00303535
0.00311334
0.00333667
0.00416751
0.00416751
0.00416751
0.00416751
0.00734072
0.00805056
0.00805056
0.00805056
0.0080697
0.0088237
0.01180982
0.01194273
0.01194273

ABCA4
KHDRBS2
PGBD5
SMOC2
ZNF385D
COL14A1
PRKCB
COBLL1
VAV3
PLAU
TRIM59
C8orf34
EGFR
EN2
CHST9
SIM1
TM4SF18
FAM157B
SLC24A4
PRDM6
COL4A1

3.69699855
5.6197865
3.79280018
4.76300444
6.24138246
4.65727301
4.12248354
2.92011069
3.40533782
3.88691296
2.76657057
4.43174171
2.23102572
4.79824185
4.50491972
5.50671866
5.06827989
5.06391749
6.00919652
5.24389641
2.68641041

3.51E-05
3.68E-05
3.74E-05
3.90E-05
3.90E-05
4.80E-05
4.91E-05
5.13E-05
5.19E-05
6.20E-05
6.48E-05
8.34E-05
8.91E-05
0.00012275
0.00012562
0.00013074
0.00015439
0.00015541
0.00018787
0.00018974
0.00022885

0.01284988
0.01284988
0.01284988
0.01284988
0.01284988
0.01516819
0.0152132
0.01545876
0.01545876
0.01812394
0.01859316
0.02349993
0.02421952
0.0317034
0.03191452
0.03231461
0.03648978
0.03648978
0.04261436
0.04261436
0.0499514

B. Complete List of Downregulated Differentially Expressed Genes
Gene Symbol
MAPK1
ARNT2
STRA6
RBP1
ANTXR1
LTBP1
AXIN2
SLFN11
PHACTR1
LYPD1
NES
PPM1F
IQGAP2
CDKN2B

logFC
-10.072382
-9.9226013
-5.394013
-5.0549638
-5.0680235
-4.1972806
-5.6951996
-3.931175
-5.3994256
-4.7769573
-6.2220916
-8.2123502
-6.557849
-8.6152355
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PValue
2.43E-09
3.89E-07
6.80E-06
8.05E-06
1.13E-05
3.59E-05
4.47E-05
8.66E-05
9.58E-05
0.00011584
0.00013137
0.00015368
0.00018348
0.00021212

FDR
4.19E-06
0.00046344
0.00405016
0.00416751
0.00545274
0.01284988
0.0144202
0.02396011
0.02559225
0.0304256
0.03231461
0.03648978
0.04243936
0.04695916
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